Charles River Laboratories (CRL) Tops Q4 EPS by 5c, Offers Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.46, $0.05 better than the analyst estimate of $2.41. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $991.25 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the consensus of $10.79.
2024 GUIDANCE |
|
Revenue growth, reported | 1.0% – 4.0% |
Impact of divestitures/(acquisitions), net | ~(0.5)% |
(Favorable)/unfavorable impact of foreign exchange | ~(0.5)% |
Revenue growth, organic (1) | 0.0% – 3.0% |
GAAP EPS estimate | $7.90 – $8.40 |
Acquisition-related amortization (2) | ~$2.40 |
Acquisition and integration-related adjustments (3) | ~$0.10 |
Costs associated with restructuring actions (4) | ~$0.25 |
Other items (5) | ~$0.25 |
Non-GAAP EPS estimate | $10.90 – $11.40 |
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Movano (MOVE) Misses Q2 EPS by 195c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
